

## **Supplementary Appendix**

**Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries**

## Content

Table S1 Contributing hospitals.....	3 – 6
Figure S1 Selection of study population.....	7
Table S2 Baseline characteristics stratified by data source and age .....	8
Table S3 Detailed specification of pre-existing cardiac disease in CAPACITY.....	9 – 10
Figure S2 Complaints at presentation stratified by age.....	11
Figure S3 Complaints at presentation stratified by age and prior history of cardiac disease.....	12
Table S4 Complaints, vitals and laboratory values at admission stratified by data source and age.....	13 – 14
Table S5 Baseline characteristics stratified by admission to a critical care unit.....	15
Table S6 Complaints, vitals and laboratory values at admission stratified by admission to a critical care unit.....	16 – 17
Table S7 Baseline characteristics stratified by mortality.....	18
Table S8 Complaints, vitals and laboratory values at admission stratified by mortality.....	19 – 20
Table S9 Outcome at discharge stratified by data source and age.....	21
Table S10 Outcome at discharge stratified by admission to a critical care unit.....	22
Table S11 Outcome at discharge stratified by mortality.....	23
Table S12 Subgroup analyses of having any history of cardiac disease among clinically relevant subgroups .....	24
Table S13 Sensitivity analyses between centers with and without a selective inclusion strategy.....	25
Table S14 Associations across data sources between pre-existent heart disease subtypes and in-hospital mortality.....	26
Table S15 Subgroup analyses for patients that were admitted to a critical care unit.....	27


**Table S1: Contributing hospitals****CAPACITY-COVID**

<b>Country</b>	<b>Site name</b>
Belgium	Antwerp University Hospital
	AZ Maria Middelares
	CHU UCL Namur – Site Godinne
	Jessa Hospital
	University Hospital Brussels
Egypt	One Day Surgery Hospital
France	SSR Val Rosay
Iran	Tehran Heart Center
Israel	EMMS Hospital
Italy	San Luigi Gonzaga University Hospital
Netherlands	Admiraal de Ruyter Hospital
	Albert Schweitzer Hospital
	Amphia Hospital
	Amstelland Hospital
	Amsterdam University Medical Center
	Antonius Hospital
	Beatrix Hospital
	Bernhoven Hospital
	Bravis Hospital
	Catharina Hospital
	Deventer Hospital
	Diakonessenhuis
	Dijklander Hospital, location Hoorn
	Elizabeth-TweeSteden Hospital
	Erasmus University Medical Center
	Franciscus Gasthuis
	Franciscus Vlietland
	Gelre Hospitals, location Apeldoorn
	Gelre Hospitals, location Zutphen
	Groene Hart Hospital
	Haaglanden Medical Center
	Hospital Group Twente
	Ikazia Hospital
	Isala
	Jeroen Bosch Hospital
	LangeLand Hospital
	Leiden University Medical Center
	Maastricht University Medical Center
	Martini Hospital
	Meander Medical Center
	Medical Center Leeuwarden
	Medisch Spectrum Twente
	Rijnstate Hospital
	Rode Kruis Hospital
	Saxenburg Medical Center
	Slingeland Hospital
	Spaarne Gasthuis
	St. Antonius Hospital
	St. Jansdal
	Treant Zorggroep
	University Medical Center Utrecht
	van Weel-Bethesda Hospital
	Zaans Medical Center
	Zuyderland Medical Center
Portugal	Hospital do Espirito Santo
	Hospital Prof. Doutor Fernando Fonesca
Russia	I.M. Sechenov First Moscow State Medical University

Saudi Arabia	King Fahd Hospital of the University
Spain	INCLIVA Research Institute, University of Valencia
	University Hospital Complex of Granada
Switzerland	University Hospital of Geneva
United Kingdom	Barts Health NHS Trust
	Leeds Teaching Hospitals NHS Trust
	Northumbria Healthcare NHS Foundation Trust
	Royal Brompton and Harefield NHS Foundation Trust
	Royal Devon and Exeter NHS Foundation Trust
	Royal Free London NHS Foundation Trust
	Salford Royal NHS Foundation Trust
	Southern Health and Social Care Trust
	The Newcastle upon Tyne Hospitals NHS Foundation Trust
	University College London Hospitals NHS Foundation Trust
	University Hospitals Bristol NHS Foundation Trust
	University Hospitals of Leicester NHS Trust
<b>LEOSS</b>	
<b>Country</b>	<b>Site name</b>
Austria	Medical University Graz
Belgium	National MS Center Melsbroek
Bosnia and Herzegovina	Clinic for Infectious Diseases University Clinical Hospital Mostar
Germany	Agaplesion Diakonie Hospital Rotenburg
	ARCIM Institute at Filderklinik
	Bethesda Hospital Bergedorf
	Bundeswehr Hospital Koblenz
	Catholic Hospital Bochum (St. Josef Hospital) Ruhr University Bochum
	Clinic Munich
	Department of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin
	Elbländ Hospital Riesa
	Elisabeth Hospital Essen
	Evangelisches Hospital Herne
	Evangelisches Hospital Saarbruecken
	German Heart Center Munich
	Hegau-Bodensee Hospital Singen
	Helios Hospital Pirna
	Hospital Braunschweig
	Hospital Bremen-Center
	Hospital Dortmund gGmbH
	Hospital Ernst von Bergmann
	Hospital Fulda
	Hospital Ingolstadt
	Hospital Kreuznacher Diakonie Hunsrück
	Hospital Leverkusen
	Hospital Maria Hilf GmbH Moenchengladbach
	Hospital Mutterhaus Borromaeerinnen Trier
	Hospital Nuremberg North
	Hospital of the Augustinian Cologne
	Hospital Oldenburg University Oldenburg
	Hospital Osnabrück
	Hospital Passau
	Hospital Preetz
	Hospital Saar Sulzbach
	Hospital Sankt Georg Leipzig
	Hospital South-Eastern Bavaria Trostberg
	Hospital St. Josef Wiesbaden
	Hospital St. Joseph-Stift Dresden
	Hospital Stuttgart
	Hospital zum Heiligen Geist, Kempen
	Hospitals of Cologne gGmbH

	Johannes Wesling Hospital Minden Ruhr University Bochum
	Maltes Hospital St. Hildegardis Cologne
	Malteser Hospital St. Franziskus Flensburg
	Marien Hospital Herne Ruhr University Bochum
	Medical practice U. Kronawitter & C. Jung Oncology Traunstein
	Medical School Hannover
	Municipal Hospital Karlsruhe
	Nephrological Center Villingen-Schwenningen
	Oberlausitz Hospital
	Otto-von-Guericke-University Magdeburg
	Petrus Hospital Wuppertal
	Practice at Ebertplatz Cologne
	Practice Dr. Boebel Reutlingen
	Practice for general medicine Drs. Elisabeth Schroedter & Gabriele Mueller-Joerger
	Practice Gotenring Cologne
	Robert-Bosch-Hospital Stuttgart
	Robert-Koch-Institute
	Sankt Vincenz Hospital Menden
	Schwerpunktpraxis Onkologie und Haematologie
	SHG Clinics Voelklingen Lung Center Saar
	Sophien- and Hufeland Clinic Weimar
	Sophien Hospital GmbH Hannover
	Srh Wald-Hospital Gera
	St. Vincenz Hospital Datteln
	St. Vincenz Hospital Limburg/Lahn
	Technical University of Munich
	Thorax-Hospital Heidelberg
	Tropical Clinic Paul-Lechler Hospital Tuebingen
	University Heart Center Freiburg Bad Krozingen
	University Hospital Augsburg
	University Hospital Bonn
	University Hospital Cologne
	University Hospital Dresden
	University Hospital Duesseldorf
	University Hospital Erlangen
	University Hospital Essen
	University Hospital Frankfurt
	University Hospital Freiburg
	University Hospital Goettingen
	University Hospital Hamburg-Eppendorf
	University Hospital Heidelberg
	University Hospital Jena
	University Hospital Muenster
	University Hospital Munich/ LMU
	University Hospital of Giessen and Marburg
	University Hospital Regensburg
	University Hospital Rostock
	University Hospital RWTH Achen
	University Hospital Saarland
	University Hospital Schleswig-Holstein - Kiel
	University Hospital Schleswig-Holstein - Luebeck
	University Hospital Tuebingen
	University Hospital Ulm
	University Hospital Wuerzburg
	University Medicine of the Johannes Gutenberg University Mainz
	Zeisigwald Hospitals Bethanien Chemnitz
Italy	Sant' Andrea Hospital University of Rome
Latvia	P. Stradiņš University Hospital
Spain	Complejo Hospitalario de Navarra
	University Hospital Arnau de Vilanova Lleida

Switzerland	Department of Neurology, Inselspital, Bern University Hospital Kantonsspital St. Gallen Luzerner Kantonsspital Neurology Neurocenter of Southern Switzerland, EOC University Hospital Basel
Turkey	Hacettepe University Pamukkale University School of Medicine University of Health Sciences Istanbul



**Figure S1:** Selection of study population

**Table S2: Baseline characteristics stratified by data source and age**


	<b>Overall</b>	<b>CAPACITY-COVID</b>		<b>LEOSS</b>		<b>P-value</b>
		<b>≤65 years</b>	<b>&gt;65 years</b>	<b>≤65 years</b>	<b>&gt;65 years</b>	
Total	16511	4303	5501	3347	3360	
<b>Age, years (%)</b>						<0.001
Median, [IQR]	NA	55 [46 – 60]	77 [72 – 84]	NA	NA	
18 – 25	239 (1.4)	94 (2.2)	0 (0.0)	145 (4.3)	0 (0.0)	
26 – 35	704 (4.3)	303 (7.0)	0 (0.0)	401 (12.0)	0 (0.0)	
36 – 45	1128 (6.8)	581 (13.5)	0 (0.0)	547 (16.3)	0 (0.0)	
46 – 55	2299 (13.9)	1309 (30.4)	0 (0.0)	990 (29.6)	0 (0.0)	
56 – 65	3280 (19.9)	2016 (46.9)	0 (0.0)	1264 (37.8)	0 (0.0)	
66 – 75	3485 (21.1)	0 (0.0)	2290 (41.6)	0 (0.0)	1195 (35.6)	
76 – 85	3720 (22.5)	0 (0.0)	2178 (39.6)	0 (0.0)	1542 (45.9)	
>85	1656 (10.0)	0 (0.0)	1033 (18.8)	0 (0.0)	623 (18.5)	
<b>Sex, female (%)</b>	6627 (40.2)	1559 (36.3)	2222 (40.5)	1311 (39.2)	1535 (45.7)	<0.001
<b>Ethnicity</b>						<0.001
Arab	496 (3.5)	345 (9.0)	151 (3.0)	0 (0.0)	0 (0.0)	
Asian	898 (6.3)	483 (12.6)	231 (4.6)	143 (5.5)	41 (1.4)	
Black	384 (2.7)	215 (5.6)	85 (1.7)	78 (3.0)	6 (0.2)	
Latin-American	21 (0.1)	14 (0.4)	7 (0.1)	0 (0.0)	0 (0.0)	
White	12120 (84.5)	2481 (64.8)	4464 (88.2)	2358 (91.4)	2817 (98.4)	
Other	416 (2.9)	293 (7.6)	123 (2.4)	0 (0.0)	0 (0.0)	
<b>BMI (kg/m<sup>2</sup>) (%)</b>						<0.001
Mean, (+/- SD)	NA	29.5 (6.3)	27.2 (5.6)	NA	NA	
Underweight (<18.5)	239 (2.3)	22 (0.8)	118 (3.3)	36 (1.7)	63 (3.2)	
Normal weight (18.5 – 24.9)	3091 (29.7)	601 (22.3)	1205 (33.3)	580 (27.6)	705 (35.3)	
Overweight (25.0 – 29.9)	3854 (37.0)	1027 (38.1)	1365 (37.7)	753 (35.8)	709 (35.5)	
Obese (30.0 – 34.9)	2069 (19.9)	619 (23.0)	643 (17.8)	450 (21.4)	357 (17.9)	
Morbidly obese (> 34.9)	1157 (11.1)	424 (15.7)	288 (8.0)	283 (13.5)	162 (8.1)	
<b>Cardiovascular risk factors (%)</b>						
Diabetes	4031 (24.9)	886 (21.0)	1649 (30.4)	494 (15.0)	1002 (30.5)	<0.001
Hypertension	7975 (49.5)	1310 (31.2)	3232 (60.3)	1089 (33.2)	2344 (71.5)	<0.001
Peripheral arterial disease	654 (4.8)	49 (1.5)	284 (7.1)	53 (1.6)	268 (8.3)	<0.001
<b>Cardiac disease (%)</b>						
Any history of cardiac disease	5198 (31.5)	654 (15.2)	2647 (48.1)	345 (10.3)	1552 (46.2)	<0.001
Arrhythmia/conduction disorder	2503 (15.3)	174 (4.0)	1277 (23.2)	113 (3.4)	939 (28.4)	<0.001
Atrial fibrillation/flutter	2004 (12.3)	96 (2.2)	953 (17.3)	100 (3.0)	855 (26.1)	<0.001
Coronary artery disease	2420 (14.8)	284 (6.6)	1090 (19.8)	225 (6.8)	821 (25.1)	<0.001
Myocardial infarction	769 (4.8)	73 (1.7)	298 (5.6)	102 (3.1)	296 (9.1)	<0.001
Heart failure	1314 (8.1)	86 (2.0)	630 (11.5)	84 (2.6)	514 (15.9)	<0.001
NYHA I/II	324 (2.0)	26 (0.6)	157 (2.9)	24 (0.7)	117 (3.5)	<0.001
NYHA III/IV	246 (1.5)	4 (0.1)	75 (1.4)	20 (0.6)	147 (4.4)	<0.001
Valvular heart disease	579 (3.6)	53 (1.2)	368 (6.7)	18 (0.6)	140 (4.3)	<0.001
<b>Comorbidities (%)</b>						
Chronic kidney disease	2196 (13.5)	189 (4.4)	991 (18.2)	223 (6.8)	793 (24.2)	<0.001
COPD	1563 (9.6)	245 (5.8)	887 (16.4)	98 (3.0)	333 (10.2)	<0.001
<b>Use cardiovascular drugs (%)</b>						
ACE-inhibitors	3021 (18.8)	491 (11.4)	1144 (20.8)	410 (13.1)	976 (31.2)	<0.001
Aldosterone antagonist	563 (3.5)	53 (1.2)	219 (4.0)	63 (1.9)	228 (7.1)	<0.001
Anti-platelet	3044 (18.7)	417 (9.7)	1419 (25.8)	274 (8.4)	934 (29.1)	<0.001
Angiotensin receptor blocker	2159 (13.5)	316 (7.4)	745 (13.6)	343 (11.0)	755 (24.4)	<0.001
Calcium-blocker	2769 (17.0)	503 (11.7)	1108 (20.2)	365 (11.2)	793 (24.7)	<0.001
Diuretic	3338 (20.5)	395 (9.2)	1515 (27.6)	291 (9.0)	1137 (35.4)	<0.001
Insulin	1204 (7.4)	278 (6.5)	431 (7.8)	146 (4.4)	349 (10.6)	<0.001
Lipid-lowering	4789 (30.5)	911 (21.2)	2459 (44.7)	363 (12.3)	1056 (35.6)	<0.001
Oral anti-diabetic	2139 (13.0)	523 (12.2)	973 (17.7)	235 (7.0)	408 (12.1)	<0.001

ACE = Angiotensin Converting Enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; IQR = Interquartile Range; NYHA = New York Heart Association; SD = Standard Deviation


**Table S3: Detailed specification of pre-existing cardiac disease in CAPACITY COVID**

	<b>Overall</b>	<b>≤65 years</b>	<b>&gt;65 years</b>	<b>P-value</b>
Total	9804	4303	5501	
<b>Arrhythmia/conduction disorder</b>				
Any	1451 (14.8)	174 (4.0)	1277 (23.2)	<0.001
Supraventricular tachycardia	1179 (12.0)	130 (3.0)	1049 (19.1)	<0.001
Paroxysmal atrial fibrillation	442 (4.5)	48 (1.1)	394 (7.2)	<0.001
Persistent atrial fibrillation	183 (1.9)	14 (0.3)	169 (3.1)	<0.001
Permanent atrial fibrillation	378 (3.9)	27 (0.6)	351 (6.4)	<0.001
Atrial flutter	989 (10.1)	89 (2.1)	900 (16.4)	<0.001
Atrial tachycardia	87 (0.9)	7 (0.2)	80 (1.5)	<0.001
AVNRT	23 (0.2)	10 (0.2)	13 (0.2)	1.00
AVRT	2 (0.0)	1 (0.0)	1 (0.0)	1.00
Unspecified	91 (0.9)	17 (0.4)	74 (1.3)	<0.001
Ventricular tachycardia (VT)	66 (0.7)	19 (0.4)	47 (0.9)	0.018
Non-sustained VT	24 (0.2)	8 (0.2)	16 (0.3)	0.402
Sustained VT	19 (0.2)	4 (0.1)	15 (0.3)	0.076
Ventricular fibrillation	26 (0.3)	8 (0.2)	18 (0.3)	0.249
Conduction disorder	154 (1.6)	13 (0.3)	141 (2.6)	<0.001
First-degree AV-block	34 (0.3)	3 (0.1)	31 (0.6)	<0.001
Second-degree AV-block	19 (0.2)	1 (0.0)	18 (0.3)	0.002
Third-degree AV-block	31 (0.3)	0 (0.0)	31 (0.6)	<0.001
Left bundle branch block	32 (0.3)	6 (0.1)	26 (0.5)	0.007
Right bundle branch block	28 (0.3)	0 (0.0)	28 (0.5)	<0.001
Long-QT	7 (0.1)	1 (0.0)	6 (0.1)	0.231
Unspecified	14 (0.1)	3 (0.1)	11 (0.2)	0.154
Sinus node dysfunction	52 (0.5)	5 (0.1)	47 (0.9)	<0.001
<b>Congenital heart disease</b>	37 (0.4)	18 (0.4)	19 (0.3)	0.676
<b>Coronary artery disease</b>	1374 (14.0)	284 (6.6)	1090 (19.8)	<0.001
Stable angina	385 (4.0)	75 (1.8)	310 (5.8)	<0.001
Unstable angina	197 (2.0)	44 (1.0)	153 (2.9)	<0.001
NSTEMI	371 (3.9)	73 (1.7)	298 (5.6)	<0.001
STEMI	361 (3.7)	77 (1.8)	284 (5.3)	<0.001
<b>Intervention coronary artery disease</b>				
PCI	637 (6.6)	142 (3.3)	495 (9.1)	<0.001
CABG	366 (3.8)	58 (1.4)	308 (5.7)	<0.001
<b>Heart failure</b>	716 (7.3)	86 (2.0)	630 (11.5)	<0.001
NYHA I/II	183 (1.9)	26 (0.6)	157 (2.9)	<0.001
NYHA III/IV	79 (0.8)	4 (0.1)	75 (1.4)	<0.001
<b>Cardiomyopathy</b>				
Arrhythmogenic	36 (0.4)	4 (0.1)	32 (0.6)	<0.001
Dilated	136 (1.4)	12 (0.3)	124 (2.3)	<0.001
Hypertensive	55 (0.6)	8 (0.2)	47 (0.9)	<0.001
Hypertrophic	21 (0.2)	6 (0.1)	15 (0.3)	0.224
Ischemic	118 (1.2)	20 (0.5)	98 (1.8)	<0.001
Myocarditis	6 (0.1)	3 (0.1)	3 (0.1)	1.000
Non-compaction	4 (0.0)	0 (0.0)	4 (0.1)	0.203
Restrictive	4 (0.0)	1 (0.0)	3 (0.1)	0.790
Toxic	4 (0.0)	2 (0.0)	2 (0.0)	1.000
Valvular	58 (0.6)	6 (0.1)	52 (1.0)	<0.001
Unspecified	217 (2.2)	15 (0.3)	202 (3.7)	<0.001
<b>Valvular heart disease</b>	421 (4.3)	53 (1.2)	368 (6.7)	<0.001
Aortic stenosis	231 (2.4)	25 (0.6)	206 (3.7)	<0.001
Aortic regurgitation	66 (0.7)	13 (0.3)	53 (1.0)	<0.001
Mitral stenosis	26 (0.3)	3 (0.1)	23 (0.4)	0.002
Mitral regurgitation	130 (1.3)	16 (0.4)	114 (2.1)	<0.001
Pulmonary regurgitation	3 (0.0)	1 (0.0)	2 (0.0)	1.000
Tricuspid regurgitation	51 (0.5)	3 (0.1)	48 (0.9)	<0.001
<b>Interventions valvular heart disease</b>				
Intervention performed	174 (1.8)	26 (0.6)	148 (2.7)	<0.001
Intervention planned	11 (0.1)	3 (0.1)	8 (0.1)	0.420

AVNRT = AV-nodal Reentrant Tachycardia; AVRT = Atrioventricular Reentrant Tachycardia; AV = Atrioventricular; CABG = Coronary Artery Bypass Surgery; NSTEMI = Non-ST-Elevation Myocardial Infarction; NYHA = New York Heart Association; PCI = Percutaneous Coronary Intervention; STEMI = ST-Elevation Myocardial Infarction; VT = Ventricular Tachycardia



**Figure S2:** Complaints at presentation stratified by age.



**Figure S3:** Complaints at presentation stratified by age and prior history of cardiac disease. Red = patients with pre-existing cardiac disease, blue = patients without pre-existing cardiac disease.

**Table S4: Complaints, vitals and laboratory values at admission stratified by data source and age**

	Overall	CAPACITY-COVID	LEOSS		P-value
		≤65 years	>65 years	≤65 years	>65 years
Total	16511	4303	5501	3347	3360
<b>Admission</b>					
Onset of symptoms to admission, days, median, [IQR]	NA	7 [3 – 10]	5 [1 – 8]	NA	NA
<b>Complaints at admission (%)</b>					
Anosmia	723 (4.6)	297 (7.4)	153 (2.9)	217 (6.7)	56 (1.7)
Chest pain	NA	535 (13.3)	318 (6.1)	NA	NA
Cough	8158 (51.8)	2713 (67.5)	2867 (55.1)	1510 (46.5)	1068 (32.7)
Dyspnea	7798 (49.8)	2694 (67.0)	3027 (58.2)	1056 (33.0)	1021 (31.7)
Fatigue	4214 (26.8)	1399 (34.8)	1790 (34.4)	471 (14.5)	554 (16.9)
Fever	8638 (54.9)	2914 (72.5)	3104 (59.6)	1491 (45.9)	1129 (34.5)
Gastrointestinal symptoms	3030 (19.2)	1120 (27.9)	1269 (24.4)	352 (10.8)	289 (8.8)
(Pre) syncope	NA	108 (2.7)	205 (3.9)	NA	NA
Orthopnea	NA	68 (1.7)	66 (1.3)	NA	NA
Palpitations	162 (1.0)	42 (1.0)	62 (1.2)	24 (0.7)	34 (1.0)
Peripheral edema	NA	13 (0.3)	42 (0.8)	NA	NA
Sore throat	1108 (7.0)	421 (10.5)	317 (6.1)	270 (8.3)	100 (3.1)
<b>Vitals at admission (%)</b>					
Temperature (°C)					<0.001
Mean, (SD)	NA	37.7 (1.1)	37.5 (1.1)	NA	NA
< 35.1	72 (0.6)	13 (0.3)	42 (0.9)	4 (0.3)	13 (0.8)
35.1 – 37.2	4898 (41.7)	1383 (36.3)	2049 (43.4)	665 (42.5)	801 (48.9)
37.3 – 37.9	2546 (21.7)	877 (23.0)	1029 (21.8)	313 (20.0)	327 (20.0)
38.0 – 38.9	2920 (24.9)	1031 (27.0)	1141 (24.2)	390 (24.9)	358 (21.9)
39.0 – 39.9	1139 (9.7)	451 (11.8)	402 (8.5)	164 (10.5)	122 (7.4)
> 39.9	158 (1.3)	59 (1.5)	54 (1.1)	28 (1.8)	17 (1.0)
Respiratory rate (breaths/min)					<0.001
Median, [IQR]	NA	21 [18 – 26]	20 [18 – 25]	NA	NA
< 16	1168 (10.8)	267 (7.2)	391 (8.5)	246 (20.4)	264 (20.0)
16 – 21	4914 (45.4)	1646 (44.5)	2059 (44.9)	596 (49.5)	613 (46.4)
22 – 29	3219 (29.8)	1179 (31.9)	1476 (32.2)	249 (20.7)	315 (23.9)
> 29	1512 (14.0)	609 (16.5)	661 (14.4)	114 (9.5)	128 (9.7)
Heart rate (beats/min)					<0.001
Mean, (SD)	NA	93 (18)	88 (20)	NA	NA
<45	51 (0.4)	10 (0.3)	27 (0.6)	7 (0.4)	7 (0.4)
45 – 59	293 (2.5)	48 (1.3)	168 (3.5)	30 (1.9)	47 (2.9)
60 – 89	6037 (51.2)	1601 (41.7)	2548 (53.7)	858 (55.1)	1030 (62.5)
90 – 119	4627 (39.3)	1881 (49.0)	1671 (35.2)	593 (38.1)	482 (29.2)
>119	775 (6.6)	297 (7.7)	327 (6.9)	68 (4.4)	83 (5.0)
Systolic blood pressure (mmHg)					<0.001
Mean, (SD)	NA	131 (21)	134 (24)	NA	NA
<80	79 (0.7)	14 (0.4)	37 (0.8)	8 (0.5)	20 (1.2)
80 – 99	566 (4.8)	166 (4.3)	259 (5.5)	59 (3.8)	82 (4.9)
100 – 119	2606 (22.1)	920 (24.1)	1028 (21.7)	357 (22.9)	301 (18.2)
120 – 139	4291 (36.5)	1564 (40.9)	1538 (32.5)	653 (41.9)	536 (32.3)
140 – 179	3827 (32.5)	1077 (28.2)	1670 (35.3)	450 (28.9)	630 (38.0)
>179	403 (3.4)	80 (2.1)	205 (4.3)	30 (1.9)	88 (5.3)
Diastolic blood pressure (mmHg)					<0.001
Mean, (SD)	NA	79 (14)	75 (15)	NA	NA
< 40	44 (0.4)	11 (0.3)	17 (0.4)	3 (0.2)	13 (0.8)
40 – 59	1218 (10.4)	278 (7.3)	649 (13.7)	84 (5.4)	207 (12.6)
60 – 89	8452 (71.9)	2773 (72.6)	3352 (70.8)	1174 (75.6)	1153 (69.9)
90 – 109	1823 (15.5)	696 (18.2)	615 (13.0)	266 (17.1)	246 (14.9)
> 109	216 (1.8)	61 (1.6)	100 (2.1)	25 (1.6)	30 (1.8)
Oxygen saturation (%)					<0.001
Median, [IQR]	NA	95 [93 – 97]	95 [92 – 97]	NA	NA
< 60	67 (0.6)	21 (0.5)	14 (0.3)	12 (0.8)	20 (1.2)
60 – 69	57 (0.5)	19 (0.5)	15 (0.3)	7 (0.5)	16 (1.0)

70 – 79	206 (1.8)	62 (1.6)	67 (1.4)	23 (1.5)	54 (3.3)	
80 – 89	1313 (11.2)	347 (9.1)	532 (11.2)	141 (9.2)	293 (17.9)	
90 – 95	4768 (40.6)	1492 (39.0)	2050 (43.3)	540 (35.1)	686 (41.9)	
96 – 100	5330 (45.4)	1887 (49.3)	2060 (43.5)	816 (53.0)	567 (34.7)	
<b>Laboratory values at admission (%)</b>						
CRP (mg/L)						<0.001
Median, [IQR]	NA	82 [36 – 157]	84 [39 – 148]	NA	NA	
< 3	540 (4.7)	81 (2.2)	62 (1.4)	251 (15.6)	146 (8.6)	
3 – 29	2664 (23.2)	680 (18.7)	803 (17.8)	641 (39.9)	540 (31.7)	
30 – 69	2605 (22.7)	844 (23.2)	1078 (23.8)	294 (18.3)	389 (22.8)	
70 – 119	2225 (19.4)	738 (20.3)	1005 (22.2)	186 (11.6)	296 (17.4)	
120 – 179	1657 (14.4)	562 (15.5)	762 (16.9)	148 (9.2)	185 (10.9)	
180 – 249	965 (8.4)	375 (10.3)	451 (10.0)	50 (3.1)	89 (5.2)	
> 249	812 (7.1)	356 (9.8)	360 (8.0)	37 (2.3)	59 (3.5)	
White blood cell count (x 10^9/L)						<0.001
Mean, (SD)	NA	8.4 (10.1)	8.5 (8.1)	NA	NA	
< 1.0	33 (0.3)	12 (0.3)	12 (0.3)	7 (0.4)	2 (0.1)	
1.0 – 3.9	1327 (11.5)	407 (11.1)	430 (9.6)	248 (15.1)	242 (14.1)	
4.0 – 7.9	6110 (53.0)	1924 (52.3)	2327 (51.9)	961 (58.5)	898 (52.2)	
8.0 – 11.9	2773 (24.1)	936 (25.4)	1169 (26.1)	308 (18.8)	360 (20.9)	
12.0 – 15.9	935 (8.1)	306 (8.3)	417 (9.3)	79 (4.8)	133 (7.7)	
16.0 – 19.9	288 (2.5)	93 (2.5)	132 (2.9)	17 (1.0)	46 (2.7)	
> 20	60 (0.5)	0 (0.0)	0 (0.0)	22 (1.3)	38 (2.2)	
Lymphocyte count (x 10^9/L)						<0.001
Mean, (SD)	NA	1.13 (0.83)	1.01 (0.96)	NA	NA	
< 0.1	70 (0.7)	9 (0.3)	17 (0.4)	22 (1.8)	22 (1.6)	
0.10 – 0.29	333 (3.5)	46 (1.5)	155 (4.0)	43 (3.4)	89 (6.4)	
0.30 – 0.49	931 (9.7)	190 (6.2)	502 (12.8)	82 (6.5)	157 (11.3)	
0.50 – 0.79	2447 (25.5)	708 (23.2)	1124 (28.7)	239 (19.0)	376 (27.1)	
0.80 – 1.49	4175 (43.4)	1530 (50.0)	1573 (40.2)	546 (43.4)	526 (37.9)	
1.50 – 2.99	1480 (15.4)	524 (17.1)	472 (12.1)	290 (23.1)	194 (14.0)	
> 3.0	176 (1.8)	50 (1.6)	68 (1.7)	35 (2.8)	23 (1.7)	
Hemoglobin (mmol/L)						<0.001
Mean, (SD)	NA	8.33 (1.27)	7.97 (1.27)	NA	NA	
< 3.73	31 (0.3)	5 (0.1)	10 (0.2)	4 (0.2)	12 (0.7)	
3.73 – 4.90	180 (1.6)	46 (1.2)	41 (0.9)	29 (1.8)	64 (3.8)	
4.91 – 6.15	764 (6.6)	178 (4.8)	333 (7.4)	90 (5.5)	163 (9.6)	
6.16 – 7.39	2101 (18.2)	509 (13.8)	971 (21.4)	250 (15.3)	371 (21.8)	
7.4 – 9.25	6469 (56.0)	2079 (56.3)	2520 (55.7)	941 (57.7)	929 (54.5)	
>= 9.25	2010 (17.4)	875 (23.7)	653 (14.4)	317 (19.4)	165 (9.7)	
Platelets (x 10^9/L)						<0.001
Mean, (SD)	NA	234 (104)	221 (102)	NA	NA	
< 10	25 (0.2)	4 (0.1)	8 (0.2)	6 (0.4)	7 (0.4)	
10 – 49	98 (0.9)	19 (0.5)	27 (0.6)	28 (1.8)	24 (1.4)	
50 – 119	931 (8.4)	201 (5.7)	407 (9.5)	123 (7.7)	200 (12.0)	
120 – 449	9681 (87.2)	3177 (89.5)	3695 (86.4)	1411 (88.3)	1398 (83.8)	
450 – 799	350 (3.2)	145 (4.1)	135 (3.2)	30 (1.9)	40 (2.4)	
800 – 1199	11 (0.1)	5 (0.1)	6 (0.1)	0 (0.0)	0 (0.0)	
Creatinine (μmol/L), Mean, (SD)	NA	98 (107)	116 (93)	NA	NA	NA

CRP = C-Reactive Protein; IQR = Interquartile Range; SD = Standard Deviation

**Table S5: Baseline characteristics stratified by admission to a critical care unit**

	<b>Overall</b>	<b>Ward</b>	<b>Critical care</b>	<b>P-value</b>
Total	16511	10287	3916	
<b>Age, years (%)</b>				<0.001
18 – 25	239 (1.4)	135 (1.3)	36 (0.9)	
26 – 35	704 (4.3)	443 (4.3)	90 (2.3)	
36 – 45	1128 (6.8)	657 (6.4)	254 (6.5)	
46 – 55	2299 (13.9)	1328 (12.9)	655 (16.7)	
56 – 65	3280 (19.9)	1792 (17.4)	1089 (27.8)	
66 – 75	3485 (21.1)	2005 (19.5)	1112 (28.4)	
76 – 85	3720 (22.5)	2601 (25.3)	598 (15.3)	
>85	1656 (10.0)	1326 (12.9)	82 (2.1)	
<b>Sex, female (%)</b>	6627 (40.2)	4438 (43.2)	1112 (28.4)	<0.001
<b>Ethnicity</b>				<0.001
Arab	496 (3.5)	335 (3.6)	161 (5.0)	
Asian	898 (6.3)	588 (6.3)	257 (7.9)	
Black	384 (2.7)	253 (2.7)	92 (2.8)	
Latin-American	21 (0.1)	14 (0.2)	7 (0.2)	
White	12120 (84.5)	7838 (84.2)	2586 (80.0)	
Other	416 (2.9)	286 (3.1)	130 (4.0)	
<b>BMI (kg/m<sup>2</sup>)</b>				<0.001
Underweight (<18.5)	239 (2.3)	169 (2.7)	32 (1.1)	
Normal weight (18.5 – 24.9)	3091 (29.7)	2044 (32.8)	642 (22.3)	
Overweight (25.0 – 29.9)	3854 (37.0)	2239 (35.9)	1163 (40.4)	
Obese (30.0 – 34.9)	2069 (19.9)	1162 (18.6)	641 (22.3)	
Morbidly obese (> 34.9)	1157 (11.1)	620 (9.9)	398 (13.8)	
<b>Cardiovascular risk factors</b>				
Diabetes	4031 (24.9)	2541 (25.1)	1022 (26.8)	0.039
Hypertension	7975 (49.5)	4923 (49.0)	1888 (49.8)	0.422
Peripheral arterial disease	654 (4.8)	405 (4.9)	149 (4.5)	0.426
<b>Cardiac disease</b>				
Any history of cardiac disease	5198 (31.5)	3519 (34.2)	1036 (26.5)	<0.001
Arrhythmia/conduction disorder	2503 (15.3)	1695 (16.5)	452 (11.7)	<0.001
Atrial fibrillation/flutter	2004 (12.3)	1309 (12.8)	369 (9.6)	<0.001
Coronary artery disease	2420 (14.8)	1504 (14.7)	566 (14.6)	0.958
Myocardial infarction	769 (4.8)	463 (4.6)	171 (4.5)	0.801
Heart failure	1314 (8.1)	876 (8.6)	231 (6.0)	<0.001
NYHA I/II	324 (2.0)	208 (2.0)	46 (1.2)	0.001
NYHA III/IV	246 (1.5)	139 (1.4)	58 (1.5)	0.609
Valvular heart disease	579 (3.6)	442 (4.3)	82 (2.1)	<0.001
<b>Comorbidities</b>				
Chronic kidney disease	2196 (13.5)	1407 (13.9)	440 (11.5)	<0.001
COPD	1563 (9.6)	1096 (10.8)	336 (8.8)	<0.001
<b>Use cardiovascular drugs</b>				
ACE-inhibitors	3021 (18.8)	1834 (18.0)	697 (19.1)	0.152
Aldosterone antagonist	563 (3.5)	356 (3.5)	103 (2.7)	0.036
Anti-platelet	3044 (18.7)	1958 (19.1)	661 (17.6)	0.042
Angiotensin receptor blocker	2159 (13.5)	1295 (12.7)	515 (14.1)	0.033
Calcium-blocker	2769 (17.0)	1629 (15.9)	731 (19.5)	<0.001
Diuretic	3338 (20.5)	2143 (20.9)	686 (18.3)	0.001
Insulin	1204 (7.4)	730 (7.1)	315 (8.2)	0.034
Lipid-lowering	4789 (30.5)	3300 (33.1)	1015 (28.3)	<0.001
Oral anti-diabetic	2139 (13.0)	1386 (13.5)	512 (13.1)	0.573

ACE = Angiotensin Converting Enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; NYHA = New York Heart Association

**Table S6: Complaints, vitals and laboratory values at admission stratified by admission to a critical care unit**

	<b>Overall</b>	<b>Ward</b>	<b>Critical care</b>	<b>P-value</b>
Total	16511	10287	3916	
<b>Admission</b>				
Onset of symptoms to admission, days, median, [IQR]	6 [2 – 9]	5 [1 – 9]	7 [3 – 9]	<0.001
<b>Complaints at admission</b>				
Anosmia	723 (4.6)	479 (4.9)	122 (3.3)	<0.001
Cough	8158 (51.8)	5303 (54.5)	1957 (52.2)	0.019
Dyspnea	7798 (49.8)	4899 (50.7)	2199 (59.1)	<0.001
Fatigue	4214 (26.8)	2946 (30.3)	922 (24.6)	<0.001
Fever	8638 (54.9)	5565 (57.2)	2188 (58.4)	0.215
Gastrointestinal symptoms	3030 (19.2)	2124 (21.8)	702 (18.7)	<0.001
Palpitations	162 (1.0)	106 (1.1)	40 (1.1)	0.986
Sore throat	1108 (7.0)	734 (7.5)	233 (6.2)	0.008
<b>Vitals at admission</b>				
Temperature (°C)				<0.001
< 35.1	72 (0.6)	45 (0.6)	22 (0.8)	
35.1 – 37.2	4898 (41.7)	3417 (43.4)	905 (33.7)	
37.3 – 37.9	2546 (21.7)	1754 (22.3)	554 (20.6)	
38.0 – 38.9	2920 (24.9)	1856 (23.6)	801 (29.8)	
39.0 – 39.9	1139 (9.7)	721 (9.2)	338 (12.6)	
> 39.9	158 (1.3)	79 (1.0)	65 (2.4)	
Respiratory rate (breaths/min)				<0.001
< 16	1168 (10.8)	764 (10.3)	217 (8.6)	
16 – 21	4914 (45.4)	3634 (49.1)	767 (30.5)	
22 – 29	3219 (29.8)	2171 (29.3)	888 (35.4)	
> 29	1512 (14.0)	832 (11.2)	639 (25.4)	
Heart rate (beats/min)				<0.001
< 45	51 (0.4)	33 (0.4)	11 (0.4)	
45 – 59	293 (2.5)	214 (2.7)	63 (2.3)	
60 – 89	6037 (51.2)	4106 (52.0)	1223 (45.2)	
90 – 119	4627 (39.3)	3067 (38.8)	1162 (42.9)	
> 119	775 (6.6)	480 (6.1)	248 (9.2)	
Systolic blood pressure (mmHg)				0.02
< 80	79 (0.7)	47 (0.6)	21 (0.8)	
80 – 99	566 (4.8)	358 (4.5)	153 (5.7)	
100 – 119	2606 (22.1)	1748 (22.1)	622 (23.2)	
120 – 139	4291 (36.5)	2918 (36.9)	923 (34.4)	
140 – 179	3827 (32.5)	2574 (32.6)	860 (32.1)	
> 179	403 (3.4)	258 (3.3)	103 (3.8)	
Diastolic blood pressure (mmHg)				<0.001
< 40	44 (0.4)	19 (0.2)	23 (0.9)	
40 – 59	1218 (10.4)	732 (9.3)	389 (14.5)	
60 – 89	8452 (71.9)	5716 (72.4)	1866 (69.7)	
90 – 109	1823 (15.5)	1268 (16.1)	355 (13.3)	
> 109	216 (1.8)	157 (2.0)	43 (1.6)	
Oxygen saturation (%)				<0.001
< 60	67 (0.6)	20 (0.3)	43 (1.6)	
60 – 69	57 (0.5)	16 (0.2)	38 (1.4)	
70 – 79	206 (1.8)	74 (0.9)	121 (4.4)	
80 – 89	1313 (11.2)	633 (8.0)	585 (21.5)	
90 – 95	4768 (40.6)	3218 (40.9)	1138 (41.7)	
96 – 100	5330 (45.4)	3904 (49.6)	802 (29.4)	
<b>Laboratory values at admission</b>				
CRP (mg/L)				<0.001
< 3	540 (4.7)	310 (4.1)	42 (1.6)	
3 – 29	2664 (23.2)	1844 (24.3)	335 (12.4)	
30 – 69	2605 (22.7)	1945 (25.6)	446 (16.5)	
70 – 119	2225 (19.4)	1561 (20.6)	524 (19.4)	
120 – 179	1657 (14.4)	1045 (13.8)	514 (19.0)	
180 – 249	965 (8.4)	539 (7.1)	391 (14.5)	

> 249	812 (7.1)	347 (4.6)	453 (16.7)	
White blood cell count (x 10 <sup>9</sup> /L)				<0.001
< 1.0	33 (0.3)	22 (0.3)	8 (0.3)	
1.0 – 3.9	1327 (11.5)	914 (12.0)	248 (9.2)	
4.0 – 7.9	6110 (53.0)	4171 (54.8)	1218 (44.9)	
8.0 – 11.9	2773 (24.1)	1793 (23.6)	764 (28.2)	
12.0 – 15.9	935 (8.1)	515 (6.8)	350 (12.9)	
16.0 – 19.9	288 (2.5)	175 (2.3)	99 (3.7)	
> 20	60 (0.5)	22 (0.3)	23 (0.8)	
Lymphocyte count (x 10 <sup>9</sup> /L)				<0.001
< 0.1	70 (0.7)	34 (0.5)	21 (1.0)	
0.10 – 0.29	333 (3.5)	206 (3.1)	94 (4.5)	
0.30 – 0.49	931 (9.7)	597 (9.0)	263 (12.7)	
0.50 – 0.79	2447 (25.5)	1620 (24.5)	626 (30.2)	
0.80 – 1.49	4175 (43.4)	2953 (44.7)	839 (40.4)	
1.50 – 2.99	1480 (15.4)	1077 (16.3)	196 (9.4)	
> 3.0	176 (1.8)	116 (1.8)	37 (1.8)	
Hemoglobin (mmol/L)				0.013
< 3.73	31 (0.3)	19 (0.2)	5 (0.2)	
3.73 – 4.90	180 (1.6)	112 (1.5)	47 (1.7)	
4.91 – 6.15	764 (6.6)	475 (6.2)	222 (8.1)	
6.16 – 7.39	2101 (18.2)	1371 (18.0)	499 (18.2)	
7.4 – 9.25	6469 (56.0)	4312 (56.5)	1475 (53.9)	
>= 9.25	2010 (17.4)	1348 (17.7)	491 (17.9)	
Platelets (x 10 <sup>9</sup> /L)				0.073
< 10	25 (0.2)	10 (0.1)	11 (0.4)	
10 – 49	98 (0.9)	58 (0.8)	24 (0.9)	
50 – 119	931 (8.4)	595 (8.2)	241 (9.1)	
120 – 449	9681 (87.2)	6386 (87.5)	2275 (86.2)	
450 – 799	350 (3.2)	240 (3.3)	86 (3.3)	
800 – 1199	11 (0.1)	8 (0.1)	3 (0.1)	

CRP = C-Reactive Protein; IQR = Interquartile Range

**Table S7: Baseline characteristics stratified by mortality**

	Overall	Discharged alive	Died during admission	P-value
Total	16511	13169	3342	
<b>Age, years (%)</b>				<0.001
18 – 25	239 (1.4)	237 (1.8)	2 (0.1)	
26 – 35	704 (4.3)	681 (5.2)	23 (0.7)	
36 – 45	1128 (6.8)	1080 (8.2)	48 (1.4)	
46 – 55	2299 (13.9)	2139 (16.2)	160 (4.8)	
56 – 65	3280 (19.9)	2873 (21.8)	407 (12.2)	
66 – 75	3485 (21.1)	2679 (20.3)	806 (24.1)	
76 – 85	3720 (22.5)	2476 (18.8)	1244 (37.2)	
>85	1656 (10.0)	1004 (7.6)	652 (19.5)	
<b>Sex, female (%)</b>	6627 (40.2)	5489 (41.7)	1138 (34.1)	<0.001
<b>Ethnicity</b>				0.001
Arab	496 (3.5)	423 (3.7)	73 (2.5)	
Asian	898 (6.3)	727 (6.4)	171 (5.8)	
Black	384 (2.7)	322 (2.8)	62 (2.1)	
Latin-American	21 (0.1)	18 (0.2)	3 (0.1)	
White	12120 (84.5)	9545 (83.9)	2575 (87.0)	
Other	416 (2.9)	339 (3.0)	77 (2.6)	
<b>BMI (kg/m<sup>2</sup>)</b>				<0.001
Underweight (<18.5)	239 (2.3)	168 (2.0)	71 (3.5)	
Normal weight (18.5 – 24.9)	3091 (29.7)	2464 (29.4)	627 (30.8)	
Overweight (25.0 – 29.9)	3854 (37.0)	3092 (36.9)	762 (37.5)	
Obese (30.0 – 34.9)	2069 (19.9)	1706 (20.4)	363 (17.9)	
Morbidly obese (> 34.9)	1157 (11.1)	947 (11.3)	210 (10.3)	
<b>Cardiovascular risk factors</b>				
Diabetes	4031 (24.9)	2966 (22.9)	1065 (32.9)	<0.001
Hypertension	7975 (49.5)	6013 (46.6)	1962 (60.8)	<0.001
Peripheral arterial disease	654 (4.8)	450 (4.0)	204 (7.9)	<0.001
<b>Cardiac disease</b>				
Any history of cardiac disease	5198 (31.5)	3653 (27.7)	1545 (46.2)	<0.001
Arrhythmia/conduction disorder	2503 (15.3)	1714 (13.1)	789 (23.9)	<0.001
Atrial fibrillation/flutter	2004 (12.3)	1358 (10.4)	646 (19.6)	<0.001
Coronary artery disease	2420 (14.8)	1676 (12.8)	744 (22.7)	<0.001
Myocardial infarction	769 (4.8)	537 (4.1)	232 (7.2)	<0.001
Heart failure	1314 (8.1)	825 (6.3)	489 (14.9)	<0.001
NYHA I/II	324 (2.0)	221 (1.7)	103 (3.1)	<0.001
NYHA III/IV	246 (1.5)	139 (1.1)	107 (3.2)	<0.001
Valvular heart disease	579 (3.6)	388 (3.0)	191 (5.8)	<0.001
<b>Comorbidities</b>				
Chronic kidney disease	2196 (13.5)	1460 (11.2)	736 (22.6)	<0.001
COPD	1563 (9.6)	1044 (8.1)	519 (16.0)	<0.001
<b>Use cardiovascular drugs</b>				
ACE-inhibitors	3021 (18.8)	2318 (18.0)	703 (22.2)	<0.001
Aldosterone antagonist	563 (3.5)	412 (3.2)	151 (4.7)	<0.001
Anti-platelet	3044 (18.7)	2230 (17.1)	814 (25.1)	<0.001
Angiotensin receptor blocker	2159 (13.5)	1719 (13.4)	440 (13.9)	0.465
Calcium-blocker	2769 (17.0)	2140 (16.4)	629 (19.5)	<0.001
Diuretic	3338 (20.5)	2351 (18.1)	987 (30.5)	<0.001
Insulin	1204 (7.4)	879 (6.7)	325 (9.9)	<0.001
Lipid-lowering	4789 (30.5)	3587 (28.5)	1202 (38.6)	<0.001
Oral anti-diabetic	2139 (13.0)	1609 (12.2)	530 (15.9)	<0.001

ACE = Angiotensin Converting Enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; NYHA = New York Heart Association

**Table S8: Complaints, vitals and laboratory values at admission stratified by mortality**

	Overall	Discharged alive	Died during admission	P-value
Total	16511	13169	3342	
<b>Admission</b>				
Onset of symptoms to admission, days, median, [IQR]	6 [2 – 9]	6 [2 – 10]	4 [1 – 7]	<0.001
<b>Complaints at admission</b>				
Anosmia	723 (4.6)	666 (5.3)	57 (1.8)	<0.001
Cough	8158 (51.8)	6660 (52.9)	1498 (47.5)	<0.001
Dyspnea	7798 (49.8)	5996 (47.9)	1802 (57.5)	<0.001
Fatigue	4214 (26.8)	3345 (26.6)	869 (27.5)	0.288
Fever	8638 (54.9)	6944 (55.2)	1694 (53.7)	0.135
Gastrointestinal symptoms	3030 (19.2)	2494 (19.8)	536 (17.0)	<0.001
Palpitations	162 (1.0)	131 (1.0)	31 (1.0)	0.847
Sore throat	1108 (7.0)	943 (7.5)	165 (5.2)	<0.001
<b>Vitals at admission</b>				
Temperature (°C)				<0.001
< 35.1	72 (0.6)	42 (0.4)	30 (1.3)	
35.1 – 37.2	4898 (41.7)	3980 (42.4)	918 (39.1)	
37.3 – 37.9	2546 (21.7)	2049 (21.8)	497 (21.1)	
38.0 – 38.9	2920 (24.9)	2300 (24.5)	620 (26.4)	
39.0 – 39.9	1139 (9.7)	891 (9.5)	248 (10.6)	
> 39.9	158 (1.3)	121 (1.3)	37 (1.6)	
Respiratory rate (breaths/min)				<0.001
< 16	1168 (10.8)	1014 (11.8)	154 (7.0)	
16 – 21	4914 (45.4)	4165 (48.4)	749 (33.8)	
22 – 29	3219 (29.8)	2431 (28.3)	788 (35.6)	
> 29	1512 (14.0)	989 (11.5)	523 (23.6)	
Heart rate (beats/min)				<0.001
< 45	51 (0.4)	40 (0.4)	11 (0.5)	
45 – 59	293 (2.5)	226 (2.4)	67 (2.8)	
60 – 89	6037 (51.2)	4904 (52.1)	1133 (48.0)	
90 – 119	4627 (39.3)	3728 (39.6)	899 (38.1)	
> 119	775 (6.6)	523 (5.6)	252 (10.7)	
Systolic blood pressure (mmHg)				<0.001
< 80	79 (0.7)	44 (0.5)	35 (1.5)	
80 – 99	566 (4.8)	402 (4.3)	164 (6.9)	
100 – 119	2606 (22.1)	2051 (21.8)	555 (23.5)	
120 – 139	4291 (36.5)	3554 (37.8)	737 (31.2)	
140 – 179	3827 (32.5)	3047 (32.4)	780 (33.0)	
> 179	403 (3.4)	310 (3.3)	93 (3.9)	
Diastolic blood pressure (mmHg)				<0.001
< 40	44 (0.4)	26 (0.3)	18 (0.8)	
40 – 59	1218 (10.4)	832 (8.9)	386 (16.4)	
60 – 89	8452 (71.9)	6816 (72.6)	1636 (69.4)	
90 – 109	1823 (15.5)	1559 (16.6)	264 (11.2)	
> 109	216 (1.8)	161 (1.7)	55 (2.3)	
Oxygen saturation (%)				<0.001
< 60	67 (0.6)	31 (0.3)	36 (1.5)	
60 – 69	57 (0.5)	23 (0.2)	34 (1.4)	
70 – 79	206 (1.8)	95 (1.0)	111 (4.7)	
80 – 89	1313 (11.2)	861 (9.2)	452 (19.1)	
90 – 95	4768 (40.6)	3800 (40.5)	968 (40.9)	
96 – 100	5330 (45.4)	4563 (48.7)	767 (32.4)	
<b>Laboratory values at admission</b>				
CRP (mg/L)				<0.001
< 3	540 (4.7)	512 (5.6)	28 (1.2)	
3 – 29	2664 (23.2)	2363 (25.8)	301 (13.0)	
30 – 69	2605 (22.7)	2146 (23.5)	459 (19.8)	
70 – 119	2225 (19.4)	1734 (19.0)	491 (21.1)	
120 – 179	1657 (14.4)	1215 (13.3)	442 (19.0)	

180 – 249	965 (8.4)	662 (7.2)	303 (13.0)	
> 249	812 (7.1)	513 (5.6)	299 (12.9)	
White blood cell count (x 10 <sup>9</sup> /L)				<0.001
< 1.0	33 (0.3)	24 (0.3)	9 (0.4)	
1.0 – 3.9	1327 (11.5)	1106 (12.0)	221 (9.5)	
4.0 – 7.9	6110 (53.0)	5034 (54.7)	1076 (46.5)	
8.0 – 11.9	2773 (24.1)	2181 (23.7)	592 (25.6)	
12.0 – 15.9	935 (8.1)	643 (7.0)	292 (12.6)	
16.0 – 19.9	288 (2.5)	186 (2.0)	102 (4.4)	
> 20	60 (0.5)	37 (0.4)	23 (1.0)	
Lymphocyte count (x 10 <sup>9</sup> /L)				<0.001
< 0.1	70 (0.7)	46 (0.6)	24 (1.2)	
0.10 – 0.29	333 (3.5)	204 (2.7)	129 (6.6)	
0.30 – 0.49	931 (9.7)	638 (8.3)	293 (15.0)	
0.50 – 0.79	2447 (25.5)	1851 (24.2)	596 (30.5)	
0.80 – 1.49	4175 (43.4)	3486 (45.5)	689 (35.2)	
1.50 – 2.99	1480 (15.4)	1290 (16.8)	190 (9.7)	
> 3.0	176 (1.8)	142 (1.9)	34 (1.7)	
Hemoglobin (mmol/L)				<0.001
< 3.73	31 (0.3)	17 (0.2)	14 (0.6)	
3.73 – 4.90	180 (1.6)	137 (1.5)	43 (1.8)	
4.91 – 6.15	764 (6.6)	526 (5.7)	238 (10.2)	
6.16 – 7.39	2101 (18.2)	1584 (17.2)	517 (22.1)	
7.4 – 9.25	6469 (56.0)	5275 (57.2)	1194 (51.0)	
>= 9.25	2010 (17.4)	1677 (18.2)	333 (14.2)	
Platelets (x 10 <sup>9</sup> /L)				<0.001
< 10	25 (0.2)	15 (0.2)	10 (0.4)	
10 – 49	98 (0.9)	75 (0.8)	23 (1.0)	
50 – 119	931 (8.4)	651 (7.3)	280 (12.5)	
120 – 449	9681 (87.2)	7827 (88.3)	1854 (83.0)	
450 – 799	350 (3.2)	286 (3.2)	64 (2.9)	
800 – 1199	11 (0.1)	9 (0.1)	2 (0.1)	

CRP = C-Reactive Protein; IQR = Interquartile Range

**Table S9: Outcome at discharge stratified by data source and age**

	Overall	CAPACITY-COVID	LEOSS		P-value
		≤65 years	>65 years	≤65 years	>65 years
Total	16511	4303	5501	3347	3360
<b>Admission</b>					
Duration of hospitalization, days, median [IQR]	NA	8 [4 – 18]	9 [5 – 18]	NA	NA
Admission to a critical care unit	3916 (27.6)	1314 (30.5)	954 (17.3)	810 (37.2)	838 (37.7)
Duration of stay critical care unit, days, median [IQR]	NA	12 [6 – 23]	12 [6 – 23]	NA	NA
<b>Treatment</b>					
Invasive ventilation	2680 (16.2)	1033 (24.1)	763 (13.9)	440 (13.2)	444 (13.2)
Non-invasive ventilation	1818 (11.1)	723 (17.1)	526 (9.6)	284 (8.5)	285 (8.5)
ECMO	316 (1.9)	106 (2.5)	16 (0.3)	145 (4.3)	49 (1.5)
<b>Complications</b>					
Cardiac					
Endocarditis	NA	2 (0.0)	7 (0.1)	NA	NA
Heart failure de novo	197 (1.2)	30 (0.7)	101 (1.8)	28 (0.8)	38 (1.1)
Myocardial infarction	95 (0.6)	14 (0.3)	32 (0.6)	11 (0.3)	38 (1.1)
Myocarditis	37 (0.2)	13 (0.3)	14 (0.3)	8 (0.2)	2 (0.1)
Pericarditis	NA	13 (0.3)	2 (0.0)	NA	NA
Ventricular arrhythmia	NA	17 (0.4)	34 (0.6)	NA	NA
Thromboembolic					
Pulmonary embolism	569 (3.5)	238 (5.6)	218 (4.0)	56 (1.7)	57 (1.7)
Stroke	106 (0.6)	21 (0.5)	50 (0.9)	5 (0.2)	30 (0.9)
Venous thrombosis	121 (0.7)	29 (0.7)	20 (0.4)	37 (1.1)	35 (1.1)
<b>Outcome</b>					
Deceased	3342 (20.2)	422 (9.8)	1819 (33.1)	218 (6.5)	883 (26.3)
					<0.001

ECMO = Extracorporeal Membrane Oxygenation; IQR = Interquartile Range

<b>Table S10: Outcome at discharge stratified by admission to a critical care unit</b>				
	<b>Overall</b>	<b>Ward</b>	<b>Critical care</b>	<b>P-value</b>
Total	16511	10287	3916	
<b>Admission</b>				
Duration of hospitalization, days, median [IQR]	9 [5 – 18]	7 [4 – 13]	21 [12 – 35]	<0.001
<b>Treatment</b>				
Invasive ventilation	2680 (16.2)	0 (0.0)	2680 (68.7)	<0.001
Non-invasive ventilation	1818 (11.1)	35 (0.3)	1783 (46.9)	<0.001
ECMO	316 (1.9)	0 (0.0)	316 (8.2)	<0.001
<b>Complications</b>				
Cardiac				
Myocarditis	37 (0.2)	13 (0.1)	23 (0.6)	<0.001
Myocardial infarction	95 (0.6)	31 (0.3)	61 (1.6)	<0.001
Heart failure de novo	197 (1.2)	97 (0.9)	93 (2.4)	<0.001
Thromboembolic				
Pulmonary embolism	569 (3.5)	144 (1.4)	405 (10.5)	<0.001
Stroke	106 (0.6)	52 (0.5)	48 (1.2)	<0.001
Venous thrombosis	121 (0.7)	28 (0.3)	86 (2.2)	<0.001
<b>Outcome</b>				
Deceased	3342 (20.2)	1799 (17.5)	1317 (33.6)	<0.001

ECMO = Extracorporeal Membrane Oxygenation; IQR = Interquartile Range

**Table S11: Outcome at discharge stratified by mortality**

	<b>Overall</b>	<b>Discharged alive</b>	<b>Died during admission</b>	<b>P-value</b>
Total	16511	13169	3342	
<b>Admission</b>				
Duration of hospitalization, days, median [IQR]	9 [5 – 18]	9 [5 – 18]	8 [5 – 16]	0.002
Admission to a critical care unit	3916 (27.6)	2599 (23.4)	1317 (42.3)	<0.001
Duration of stay critical care unit, days, median [IQR]	12 [6 – 23]	13 [6 – 25]	11 [6 – 19]	<0.001
<b>Treatment</b>				
Invasive ventilation	2680 (16.2)	1608 (12.2)	1072 (32.1)	<0.001
Non-invasive ventilation	1818 (11.1)	1267 (9.7)	551 (16.7)	<0.001
ECMO	316 (1.9)	148 (1.1)	168 (5.1)	<0.001
<b>Complications</b>				
Cardiac				
Myocarditis	37 (0.2)	24 (0.2)	13 (0.4)	0.039
Myocardial infarction	95 (0.6)	40 (0.3)	55 (1.7)	<0.001
Heart failure de novo	197 (1.2)	92 (0.7)	105 (3.1)	<0.001
Thromboembolic				
Pulmonary embolism	569 (3.5)	404 (3.1)	165 (5.0)	<0.001
Stroke	106 (0.6)	63 (0.5)	43 (1.3)	<0.001
Venous thrombosis	121 (0.7)	86 (0.7)	35 (1.1)	0.021

ECMO = Extracorporeal Membrane Oxygenation; IQR = Interquartile Range

**Table S12: Subgroup analyses of having any history of cardiac disease among clinically relevant subgroups**

	p-value interaction	RR [95% CI]	p-value subgroup
<b>Multivariable adjusted*</b>			
<b>Age</b>	0.10		
≤65 years		1.25 [1.04 – 1.50]	0.02
>65 years		1.06 [0.99 – 1.13]	0.08
<b>Sex</b>	0.09		
Female		1.16 [1.05 – 1.29]	<0.001
Male		1.04 [0.97 – 1.12]	0.25
<b>BMI (kg/m<sup>2</sup>)</b>	0.18		
<30		1.11 [1.03 – 1.20]	0.01
≥30		1.00 [0.87 -1.14]	0.98
<b>Diabetes</b>	0.27		
No		1.12 [1.03 – 1.20]	<0.001
Yes		1.03 [0.93 – 1.14]	0.52
<b>Hypertension</b>	0.21		
No		1.14 [1.03 – 1.26]	0.01
Yes		1.05 [0.98 – 1.14]	0.18
<b>Chronic kidney disease</b>	0.33		
No		1.10 [1.02 – 1.18]	0.01
Yes		1.03 [0.91 – 1.16]	0.69
<b>COPD</b>	0.54		
No		1.07 [1.00 – 1.15]	0.04
Yes		1.13 [0.98 – 1.30]	0.10

\* Multivariable models are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Central Europe, Middle – East, Netherlands/Belgium, Russia, Southern – Europe and the United Kingdom).

**Table S13: Sensitivity analyses between centers with and without a selective inclusion strategy**

	Total cohort	Cohort with exclusion of patients included from centers with selective inclusion		
	RR [95% CI]	p-value*	RR [95% CI]	p-value*
<b>Crude</b>				
Any cardiac history	1.87 [1.76 – 1.99]	<0.01	1.89 [1.78 – 2.01]	<0.01
Arrhythmia/conduction disorder	1.73 [1.62 – 1.85]	<0.01	1.75 [1.63 – 1.88]	<0.01
Atrial fibrillation	1.73 [1.61 – 1.86]	<0.01	1.76 [1.63 – 1.89]	<0.01
Coronary artery disease	1.68 [1.57 – 1.80]	<0.01	1.70 [1.58 – 1.83]	<0.01
Myocardial infarction	1.55 [1.39 – 1.74]	<0.01	1.56 [1.39 – 1.75]	<0.01
Heart failure	1.99 [1.84 – 2.15]	<0.01	2.00 [1.84 – 2.16]	<0.01
NYHA I/II	1.72 [1.47 – 2.02]	<0.01	1.72 [1.46 – 2.02]	<0.01
NYHA III/IV	2.37 [2.06 – 2.74]	<0.01	2.39 [2.07 – 2.76]	<0.01
Valvular disease	1.68 [1.49 – 1.89]	<0.01	1.68 [1.47 – 1.91]	<0.01
<b>Age and sex adjusted</b>				
Any cardiac history	1.13 [1.06 – 1.20]	<0.018	1.13 [1.07 – 1.21]	<0.018
Arrhythmia/conduction disorder	1.06 [0.99 – 1.13]	0.72	1.06 [0.99 – 1.14]	0.90
Atrial fibrillation	1.07 [1.00 – 1.15]	0.70	1.08 [1.00 – 1.16]	0.50
Coronary artery disease	1.14 [1.06 – 1.22]	<0.018	1.14 [1.06 – 1.22]	<0.018
Myocardial infarction	1.10 [0.99 – 1.22]	0.72	1.09 [0.98 – 1.22]	0.96
Heart failure	1.31 [1.21 – 1.42]	<0.018	1.30 [1.20 – 1.41]	<0.018
NYHA I/II	1.16 [0.98 – 1.36]	0.72	1.14 [0.97 – 1.35]	0.96
NYHA III/IV	1.53 [1.32 – 1.78]	<0.018	1.53 [1.31 – 1.77]	<0.018
Valvular disease	1.11 [0.98 – 1.25]	0.72	1.10 [0.97 – 1.25]	0.96
<b>Multivariable adjusted**</b>				
Any cardiac disease	1.08 [1.02 – 1.15]	0.12	1.09 [1.02 – 1.17]	0.12
Arrhythmia/conduction disorder	1.01 [0.94 – 1.08]	1.00	1.02 [0.95 – 1.10]	1.00
Atrial fibrillation	1.04 [0.97 – 1.12]	1.00	1.05 [0.97 – 1.14]	0.96
Coronary artery disease	1.10 [1.03 – 1.18]	0.12	1.11 [1.03 – 1.19]	0.12
Myocardial infarction	1.07 [0.96 – 1.19]	1.00	1.07 [0.95 – 1.19]	1.00
Heart failure	1.19 [1.10 – 1.30]	<0.018	1.19 [1.10 – 1.30]	<0.018
NYHA I/II	1.05 [0.90 – 1.24]	1.00	1.04 [0.89 – 1.23]	1.00
NYHA III/IV	1.41 [1.20 – 1.64]	<0.018	1.41 [1.21 – 1.65]	<0.018
Valvular disease	1.03 [0.91 – 1.16]	1.00	1.02 [0.90 – 1.16]	1.00

\* p-values are adjusted for multiple testing by the Holm-Bonferroni method.

\*\* Multivariable models are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Central Europe, Middle – East, Netherlands/Belgium, Russia, Southern – Europe and the United Kingdom). The models testing the association between a specific heart disease subtype and in-hospital mortality are also adjusted for the presence of other cardiac comorbidities (i.e. the model testing the association between heart failure and in-hospital mortality is adjusted for arrhythmia/conduction disorder, coronary artery disease and valvular disease).

**Table S14: Associations across data sources between pre-existent heart disease subtypes and in-hospital mortality**

	CAPACITY-COVID		LEOSS		Total	
	RR [95% CI]	p-value*	RR [95% CI]	p-value*	RR [95% CI]	p-value*
<b>Crude</b>						
Any cardiac history	1.60 [1.49 – 1.72]	<0.01	2.43 [2.19 – 2.70]	<0.01	1.87 [1.76 – 1.99]	<0.01
Arrhythmia/conduction disorder	1.57 [1.44 – 1.70]	<0.01	2.10 [1.87 – 2.35]	<0.01	1.73 [1.62 – 1.85]	<0.01
Atrial fibrillation	1.61 [1.47 – 1.76]	<0.01	2.09 [1.86 – 2.35]	<0.01	1.73 [1.61 – 1.86]	<0.01
Coronary artery disease	1.49 [1.37 – 1.63]	<0.01	2.14 [1.91 – 2.39]	<0.01	1.68 [1.57 – 1.80]	<0.01
Myocardial infarction	1.35 [1.16 – 1.58]	<0.01	1.98 [1.70 – 2.32]	<0.01	1.55 [1.39 – 1.74]	<0.01
Heart failure	1.76 [1.59 – 1.94]	<0.01	2.52 [2.23 – 2.85]	<0.01	1.99 [1.84 – 2.15]	<0.01
NYHA I/II	1.58 [1.34 – 1.87]	<0.01	2.02 [1.55 – 2.63]	<0.01	1.72 [1.47 – 2.02]	<0.01
NYHA III/IV	2.17 [1.76 – 2.67]	<0.01	2.94 [2.46 – 3.52]	<0.01	2.37 [2.06 – 2.74]	<0.01
Valvular disease	1.54 [1.34 – 1.76]	<0.01	1.87 [1.46 – 2.40]	<0.01	1.68 [1.49 – 1.89]	<0.01
<b>Age and sex adjusted</b>						
Any cardiac history	1.04 [0.97 – 1.12]	1.00	1.30 [1.17 – 1.46]	<0.018	1.13 [1.06 – 1.20]	<0.018
Arrhythmia/conduction disorder	1.03 [0.95 – 1.12]	1.00	1.14 [1.01 – 1.27]	0.24	1.06 [0.99 – 1.13]	0.72
Atrial fibrillation	1.06 [0.97 – 1.16]	1.00	1.15 [1.03 – 1.29]	0.20	1.07 [1.00 – 1.15]	0.70
Coronary artery disease	1.07 [0.98 – 1.17]	1.00	1.30 [1.16 – 1.46]	<0.018	1.14 [1.06 – 1.22]	<0.018
Myocardial infarction	1.0 [0.86 – 1.16]	1.00	1.29 [1.10 – 1.51]	<0.018	1.10 [0.99 – 1.22]	0.72
Heart failure	1.22 [1.11 – 1.35]	<0.018	1.51 [1.33 – 1.71]	<0.018	1.31 [1.21 – 1.42]	<0.018
NYHA I/II	1.11 [0.94 – 1.32]	1.00	1.24 [0.95 – 1.63]	0.91	1.16 [0.98 – 1.36]	0.72
NYHA III/IV	1.48 [1.19 – 1.84]	<0.018	1.72 [1.42 – 2.08]	<0.018	1.53 [1.32 – 1.78]	<0.018
Valvular disease	1.08 [0.95 – 1.24]	1.00	1.05 [0.83 – 1.34]	1.00	1.11 [0.98 – 1.25]	0.72
<b>Multivariable adjusted**</b>						
Any cardiac disease	1.03 [0.96 – 1.11]	1.00	1.18 [1.05 – 1.32]	<0.018	1.08 [1.02 – 1.15]	0.12
Arrhythmia/conduction disorder	1.01 [0.93 – 1.11]	1.00	0.99 [0.88 – 1.12]	1.00	1.01 [0.94 – 1.08]	1.00
Atrial fibrillation	1.04 [0.95 – 1.15]	1.00	1.01 [0.90 – 1.14]	1.00	1.04 [0.97 – 1.12]	1.00
Coronary artery disease	1.05 [0.96 – 1.15]	1.00	1.16 [1.03 – 1.30]	0.20	1.10 [1.03 – 1.18]	0.12
Myocardial infarction	0.98 [0.84 – 1.13]	1.00	1.13 [0.96 – 1.32]	0.91	1.07 [0.96 – 1.19]	1.00
Heart failure	1.11 [1.00 – 1.24]	0.75	1.30 [1.13 – 1.49]	<0.018	1.19 [1.10 – 1.30]	<0.018
NYHA I/II	1.02 [0.86 – 1.22]	1.00	1.11 [0.85 – 1.46]	1.00	1.05 [0.90 – 1.24]	1.00
NYHA III/IV	1.33 [1.06 – 1.66]	0.32	1.45 [1.19 – 1.77]	<0.018	1.41 [1.20 – 1.64]	<0.018
Valvular disease	1.06 [0.93 – 1.22]	1.00	0.94 [0.74 – 1.20]	1.00	1.03 [0.91 – 1.16]	1.00

\* p-values are adjusted for multiple testing by the Holm-Bonferroni method.

\*\* Multivariable models are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Central Europe, Middle – East, Netherlands/Belgium, Russia, Southern – Europe and the United Kingdom). The models testing the association between a specific heart disease subtype and in-hospital mortality are also adjusted for the presence of other cardiac comorbidities (i.e. the model testing the association between heart failure and in-hospital mortality is adjusted for arrhythmia/conduction disorder, coronary artery disease and valvular disease).

**Table S15: Subgroup analyses for patients that were admitted to a critical care unit**

		Patients only admitted to the ward		Patients admitted to a critical care unit	
	p-value interaction	RR [95% CI]	p-value subgroup	RR [95% CI]	p-value subgroup
<b>Multivariable adjusted**</b>					
Any cardiac disease	<0.001	1.26 [1.16 – 1.37]	<0.001	0.96 [0.88 – 1.06]	0.40
Arrhythmia/conduction disorder	<0.001	1.17 [1.07 – 1.28]	<0.001	0.82 [0.73 – 0.92]	<0.001
Atrial fibrillation	<0.001	1.22 [1.11 – 1.33]	<0.001	0.80 [0.71 – 0.91]	<0.001
Coronary artery disease	0.07	1.18 [1.08 – 1.29]	0.08	1.03 [0.93 – 1.15]	0.55
Myocardial infarction	0.57	1.12 [0.97 – 1.29]	0.12	1.05 [0.89 – 1.24]	0.57
Heart failure	0.01	1.29 [1.17 – 1.43]	<0.001	1.00 [0.86 – 1.17]	0.97
NYHA I/II	0.07	1.15 [0.98 – 1.35]	0.10	0.91 [0.71 – 1.17]	0.46
NYHA III/IV	0.01	1.55 [1.28 – 1.87]	<0.001	1.09 [0.88 – 1.35]	0.41
Valvular disease	<0.001	1.23 [1.07 – 1.41]	<0.001	0.72 [0.55 – 0.95]	0.02

\* Multivariable models are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Central Europe, Middle – East, Benelux, Russia, Southern – Europe and the United Kingdom). The models testing the association between a specific heart disease subtype and in-hospital mortality are also adjusted for the presence of other cardiac comorbidities (i.e. the model testing the association between heart failure and in-hospital mortality is adjusted for arrhythmia/conduction disorder, coronary artery disease and valvular disease).